Breast Carcinoma
|
0.600 |
GenomicAlterations
|
disease |
CGI |
|
|
|
Breast Carcinoma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer.
|
3664511 |
1987 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer.
|
3798106 |
1987 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical localization of c-erbB-2 in human breast carcinomas.
|
3330998 |
1987 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.
|
2885574 |
1987 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.
|
3330785 |
1987 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have performed an analysis of ras, c-myc, c-myb, c-erbB1 and c-erbB2 oncogenes in 100 surgical samples of human breast carcinomas.
|
3293644 |
1988 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Amplification of the neu (or c-erbB-2 or HER) oncogene is found to be present in 15-30% of human breast carcinomas and has been reported to correlate with poor prognosis.
|
3360152 |
1988 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.
|
2849974 |
1988 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This is the first study showing that a determination of the level of c-erbB-2 protein in paraffin-embedded tumor sections may have prognostic value for the course of human breast cancer.
|
2893663 |
1988 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This serum specifically reacted with a 185 kilodaltons neu protein in SKBR-3 cells, a mammary carcinoma cell line with amplified neu.
|
3285295 |
1988 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
|
2903446 |
1988 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Comparison of erbB-2 overexpression with clinical disease parameters revealed a correlation of this alteration with inflammatory mammary carcinoma (P = 0.042) implying an association of elevated erbB-2 protein levels with enhanced malignancy of the tumor cell in vivo.
|
2564657 |
1989 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, immuno-histological diagnosis with anti-c-erbB-2 antibody might be useful as an indicator to predict lymph-node involvement in breast cancer.
|
2576425 |
1989 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas.
|
2569035 |
1989 |
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The c-myc gene was amplified 5-7-fold in two adenocarcinomas, the H-ras gene 3 5-fold in one adenocarcinoma, while the K-ras and the neu gene were amplified in lung metastases from a colorectal and a breast cancer primary respectively.
|
2547415 |
1989 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 (or c-erbB-2), the human homolog of the rat neu proto-oncogene, encodes a transmembrane glycoprotein of the tyrosine kinase family that appears to play an important role in human breast carcinoma.
|
2565808 |
1989 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.
|
2573426 |
1989 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A similar analysis was performed for two other proto-oncogenes, c-erbB-2 and c-myc, also suspected of playing a role in the development of human breast cancer.
|
2611995 |
1989 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Alterations in the gene copy numbers of the proto-oncogenes HER2/neu and c-myc in primary human breast cancer investigated in 73 patients.
|
2563720 |
1989 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER-2/neu oncogene protein and prognosis in breast cancer.
|
2569032 |
1989 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
There was no association of erbB-2 expression or gene amplification with clinical stage of breast carcinoma or axillary lymph node involvement.
|
2568168 |
1989 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
C-erbB-2 and epidermal growth factor receptor (EGFR) genes were independently shown to be associated with breast cancer progression.
|
2563719 |
1989 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Some of these mutations involve amplification of protooncogenes (c-myc, c-erbB-2, and int-2) that have been shown to contribute to experimentally induced breast cancer in mouse model systems.
|
2667653 |
1989 |